Jonathan Mark Aukeman, CRNA | |
9300 Dewitt Loop, Fort Belvoir, VA 22060-5285 | |
(571) 231-3224 | |
Not Available |
Full Name | Jonathan Mark Aukeman |
---|---|
Gender | Male |
Speciality | Certified Registered Nurse Anesthetist (crna) |
Experience | 8 Years |
Location | 9300 Dewitt Loop, Fort Belvoir, Virginia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215380134 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163W00000X | Registered Nurse | 4704261198 (Michigan) | Secondary |
367500000X | Nurse Anesthetist, Certified Registered | 4704261198 (Michigan) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Inova Cares - Community | 9537526330 | 208 |
Inova Cares - Community | 9537526330 | 208 |
News Archive
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment-resistant depression or TRD is exactly what it sounds like: a form of mental illness that defies effective therapy. It is not rare, with an estimated 3 million persons in the United States suffering from TRD.
Now, researchers at Clarkson University are looking at a population located near a major international trucking route to determine whether high levels of diesel emissions released in the air may be linked to increased rates of respiratory illnesses in an adjacent community.
› Verified 2 days ago
Entity Name | American Anesthesiology Of Virginia Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1417994872 PECOS PAC ID: 6800790023 Enrollment ID: O20080812000606 |
News Archive
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment-resistant depression or TRD is exactly what it sounds like: a form of mental illness that defies effective therapy. It is not rare, with an estimated 3 million persons in the United States suffering from TRD.
Now, researchers at Clarkson University are looking at a population located near a major international trucking route to determine whether high levels of diesel emissions released in the air may be linked to increased rates of respiratory illnesses in an adjacent community.
› Verified 2 days ago
Entity Name | Inova Cares - Community |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1861131906 PECOS PAC ID: 9537526330 Enrollment ID: O20230609002576 |
News Archive
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment-resistant depression or TRD is exactly what it sounds like: a form of mental illness that defies effective therapy. It is not rare, with an estimated 3 million persons in the United States suffering from TRD.
Now, researchers at Clarkson University are looking at a population located near a major international trucking route to determine whether high levels of diesel emissions released in the air may be linked to increased rates of respiratory illnesses in an adjacent community.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Jonathan Mark Aukeman, CRNA 9300 Dewitt Loop, Fort Belvoir, VA 22060-5285 Ph: () - | Jonathan Mark Aukeman, CRNA 9300 Dewitt Loop, Fort Belvoir, VA 22060-5285 Ph: (571) 231-3224 |
News Archive
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment-resistant depression or TRD is exactly what it sounds like: a form of mental illness that defies effective therapy. It is not rare, with an estimated 3 million persons in the United States suffering from TRD.
Now, researchers at Clarkson University are looking at a population located near a major international trucking route to determine whether high levels of diesel emissions released in the air may be linked to increased rates of respiratory illnesses in an adjacent community.
› Verified 2 days ago
Mrs. Constance Louise Jenkins, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 9300 Dewitt Loop, Fort Belvoir, VA 22060 Phone: 571-231-2890 | |
Mrs. Connie Jean Moore, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 9501 Farrell Rd, Fort Belvoir, VA 22060 Phone: 703-805-0004 | |
Mr. Vincent Bernard Bogan, MSN-CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 9501 Farrell Rd, Dewitt Army Community Hospital, Fort Belvoir, VA 22060 Phone: 703-805-0342 Fax: 703-805-0731 | |
Randy Graham, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 9300 Dewitt Loop, Fort Belvoir, VA 22060 Phone: 571-231-3224 | |
Jacob Macgregor, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 9300 Dewit Loop, Fort Belvoir Community Hospital, Fort Belvoir, VA 22060 Phone: 571-231-4578 | |
Mrs. Cathy Elizabeth Peuterbaugh, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: Us Army Medical Dept, 9501 Farrell Rd, Fort Belvoir, VA 22060 Phone: 703-805-0923 | |
Chris Noel Angeles, CRNA, MSN Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 9300 Dewitt Loop, Fort Belvoir Community Hospital, Fort Belvoir, VA 22060 Phone: 571-231-3224 |